Compliance Notice For laboratory and research use only. Not for human consumption. Nothing in this article constitutes medical advice, dosing guidance, or instructions for personal use. |
Anyone comparing GHRH-class research peptides eventually runs into the same wall: sermorelin and CJC-1295 look similar on paper, get referenced interchangeably in forums, and yet behave very differently once you look at half-life, stability, and study design. Picking the wrong one for a research protocol can mean re-running an entire study timeline.
Featured Products
This guide breaks down sermorelin vs CJC-1295 the way a lab actually needs it broken down — molecular structure, mechanism of action, half-life and duration, DAC vs no-DAC formulations, stability and storage, and how researchers verify purity before a compound ever goes into a study. Every comparison here is framed for laboratory and research use, not personal administration.
By the end, you'll be able to explain the core difference between sermorelin and CJC-1295 in one sentence, know which formulation questions to ask a supplier, and understand where 99 Purity Peptides' third-party testing fits into that decision.
Quick Answer: Sermorelin vs CJC-1295 in 60 Words
Key Difference Sermorelin is a shorter GHRH(1-29) analog with a half-life of roughly 10-20 minutes, producing a pulsatile release pattern that mirrors natural GHRH signaling. CJC-1295 is a modified GHRH analog available with or without Drug Affinity Complex (DAC); the DAC version extends half-life to several days by binding serum albumin, producing sustained rather than pulsatile signaling in research models. |
Sermorelin vs CJC-1295: Comparison Chart
Attribute | Sermorelin (Acetate) | CJC-1295 (with DAC) | CJC-1295 (no DAC / Mod GRF 1-29) |
|---|---|---|---|
Peptide class | GHRH(1-29) analog | Modified GHRH analog + DAC | Modified GHRH(1-29) analog |
Approx. molecular weight | ~3,357 Da | ~3,647 Da | ~3,368 Da |
Approx. half-life (in vitro/in vivo research models) | 10-20 minutes | ~6-8 days | ~30 minutes |
Release pattern studied | Pulsatile | Sustained/continuous | Pulsatile, extended vs. sermorelin |
Structural basis | Native GHRH(1-29) sequence, acetate salt | GHRH(1-29) analog + Lys-linked DAC (maleimidopropionic acid) | GHRH(1-29) analog, amino acid substitutions for stability |
Typical research framing | Baseline/physiologic GHRH studies | Sustained-signaling and long-interval protocols | Intermediate-duration signaling studies |
Reconstitution | Bacteriostatic water, standard lyophilized handling | Bacteriostatic water, standard lyophilized handling | Bacteriostatic water, standard lyophilized handling |
Room-temp solution stability (general peptide chemistry) | Lower — recommend refrigeration/freezing after reconstitution | Higher relative stability due to DAC conjugation | Moderate |
Figures above reflect commonly cited research-literature ranges for these compounds and can vary by study design, buffer, and storage conditions — always confirm against the specific batch's certificate of analysis (COA) rather than a general reference table.
What Is Sermorelin?
Sermorelin (sermorelin acetate) is a synthetic 29-amino-acid peptide corresponding to the biologically active fragment of human growth hormone-releasing hormone (GHRH). In research settings, it's used to study the hypothalamic-pituitary axis and pulsatile growth hormone (GH) release without introducing a fully synthetic, long-acting analog into the model.
Sermorelin's Structure and Mechanism
Sermorelin reproduces the first 29 amino acids of endogenous GHRH — the minimum fragment retaining full biological activity in binding studies. It's studied for its interaction with the growth hormone-releasing hormone receptor (GHRH-R) on the pituitary gland, where receptor binding is associated with pulsatile somatotropin release patterns in research models.
Why Researchers Choose Sermorelin
- Closer structural match to native GHRH, useful for baseline physiologic comparison studies
- Short half-life supports pulsatile-release study designs
- Extensive existing research literature relative to newer synthetic analogs
- Well-characterized reconstitution and handling profile
What Is CJC-1295?
CJC-1295 is a modified GHRH(1-29) analog engineered with amino acid substitutions that increase resistance to enzymatic degradation. It's available in two distinct research formulations that behave very differently — this is the single most common point of confusion in sermorelin vs CJC-1295 comparisons.
CJC-1295 with DAC
The "DAC" (Drug Affinity Complex) version is conjugated to a maleimidopropionic acid linker that binds covalently to serum albumin after administration in research models. This albumin binding is the mechanism researchers cite for its extended half-life — commonly reported in the range of several days rather than minutes — producing a sustained, non-pulsatile GHRH signal in study designs.
CJC-1295 without DAC (Mod GRF 1-29)
Sometimes labeled Mod GRF (1-29), this version omits the DAC conjugation. It retains the stability-enhancing amino acid substitutions but clears at a rate closer to — though still generally longer than — sermorelin, making it a middle-ground option in half-life comparisons and a common substitute where a pulsatile pattern is still the study objective but greater peptide stability is needed than native sermorelin offers.
Common Mistake Treating "CJC-1295" as a single compound. Always confirm with a supplier's COA whether a given CJC-1295 vial is the DAC or no-DAC formulation — the half-life difference between the two is roughly 100-fold and changes the entire research protocol design. |
Mechanism of Action Compared
Both compounds are studied as GHRH-receptor agonists, meaning the proposed mechanism in each case is binding to GHRH-R on pituitary somatotroph cells. Where they diverge is in the resulting signaling pattern observed in research models:
- Sermorelin: short receptor occupancy, consistent with the pulsatile GH release seen with endogenous GHRH
- CJC-1295 no-DAC: moderately extended receptor occupancy relative to sermorelin
- CJC-1295 with DAC: prolonged occupancy tied to slow release from the albumin-bound complex, associated with sustained rather than pulsatile signaling in study data
This distinction matters for study design specifically because pulsatility itself — not just total signaling exposure — is a variable of interest in much of the GH-axis research literature.
Half-Life and Duration of Action
Compound | Reported Half-Life Range | Signaling Pattern |
|---|---|---|
Sermorelin | 10-20 minutes | Pulsatile |
CJC-1295 (no DAC) | ~30 minutes | Pulsatile, extended |
CJC-1295 (with DAC) | ~6-8 days | Sustained/continuous |
Half-life differences of this magnitude are the primary reason researchers select one compound over another — a study designed around repeated short pulses cannot be substituted with a long-acting DAC formulation without redesigning the sampling schedule entirely.
Stability and Storage Considerations
Lyophilized (freeze-dried) sermorelin and CJC-1295 are both generally stable when stored per supplier guidance prior to reconstitution. Once reconstituted with bacteriostatic water, general peptide chemistry principles apply: minimize freeze-thaw cycles, avoid extended room-temperature exposure, and store reconstituted vials refrigerated unless the COA specifies otherwise.
General Storage Guidelines (Research Context Only)
- Store lyophilized peptide vials at -20°C or below for long-term storage; refrigeration is typically sufficient for shorter windows per supplier documentation
- Reconstitute only with bacteriostatic water rated for peptide use
- Keep reconstituted solutions refrigerated (2-8°C) and shielded from light
- Avoid repeated freeze-thaw cycling, which is associated with peptide degradation and aggregation in the broader research literature
- Log reconstitution date and discard per the supplier's documented stability window
For a full walkthrough of degradation mechanisms, cold-chain shipping, and lab storage equipment, see our dedicated peptide storage and handling guide.
Purity, Testing, and Certificate of Analysis (COA)
Purity verification is where sermorelin vs CJC-1295 comparisons stop being theoretical and start affecting actual research outcomes. A peptide with unverified purity introduces a confound into any study — you can't attribute results to the compound if you don't know what's actually in the vial.
What a Legitimate COA Should Include
- HPLC (High-Performance Liquid Chromatography) purity percentage
- Mass spectrometry confirmation of molecular identity
- Batch or lot number matching the vial received
- Endotoxin testing results where applicable
- Third-party lab name and testing date, not just an in-house certificate
Key Takeaway Independently verified, third-party COAs — not vendor-generated purity claims — are the baseline for citation-worthy, EEAT-aligned sourcing decisions in peptide research. |
99 Purity Peptides publishes third-party HPLC and mass spectrometry verification for its sermorelin and CJC-1295 (both DAC and no-DAC) research vials, so researchers can confirm identity and purity before a compound enters a study protocol.
Can Sermorelin and CJC-1295 Be Studied Together?
Some research protocols examine sermorelin and a GHRP-class secretagogue (such as ipamorelin) in combination, since the two act on different receptor pathways — GHRH-R versus the growth hormone secretagogue receptor (GHSR). CJC-1295 is likewise studied alongside GHRP-class compounds in combination-protocol literature. Combining sermorelin with CJC-1295 directly is less commonly represented in the literature, since both target the same GHRH-R pathway and a study would need a clear rationale for using two GHRH analogs with very different half-lives in the same design.
If a protocol calls for a GHRH-plus-GHRP combination framework, see our dedicated CJC-1295 and Ipamorelin combination research articles linked below.
Choosing Between Sermorelin and CJC-1295 for a Research Protocol
Use this checklist to match compound selection to study design — this is a research-design framework, not usage instruction:
- Does the protocol require a pulsatile signaling pattern? → Sermorelin or CJC-1295 no-DAC
- Does the protocol require sustained, continuous receptor signaling? → CJC-1295 with DAC
- Is the study comparing results against native GHRH physiology? → Sermorelin, as the closer structural analog
- Does the sampling schedule allow only infrequent measurement intervals? → CJC-1295 with DAC's longer half-life reduces sampling frequency demands
- Is peptide stability during a longer study window a priority? → CJC-1295 (either formulation) generally offers improved stability over native-sequence sermorelin
- Has the supplier provided a current, third-party COA for the specific batch? → Required regardless of which compound is selected
Common Mistakes in GHRH Peptide Research Sourcing
- Assuming all CJC-1295 listings are the DAC version without checking the COA
- Comparing half-life figures from different sources without confirming study conditions
- Skipping third-party purity verification in favor of a supplier's in-house claim
- Reconstituting with non-bacteriostatic water or an unrated diluent
- Storing reconstituted peptide at room temperature for extended periods
- Treating forum-sourced anecdotes as a substitute for peer-reviewed or COA-backed data
Where to Source Research-Grade Sermorelin and CJC-1295
99 Purity Peptides supplies sermorelin acetate and both CJC-1295 formulations (with and without DAC) as research-use-only compounds, each shipped with third-party HPLC and mass spectrometry documentation. All product listings are framed explicitly for laboratory and research use — not for human consumption — consistent with FDA and FTC guidance for RUO compound suppliers.
Key Takeaways
- Sermorelin is the native-sequence GHRH(1-29) analog with a short, pulsatile half-life of roughly 10-20 minutes.
- CJC-1295 comes in two distinct formulations — with DAC (half-life of several days, sustained signaling) and without DAC/Mod GRF (1-29) (half-life ~30 minutes, extended pulsatile signaling) — and they are not interchangeable in study design.
- Half-life and signaling pattern, not "potency," are the primary variables that should drive compound selection for a given protocol.
- Reconstituted peptide stability depends on proper bacteriostatic water use, refrigeration, and avoiding freeze-thaw cycling.
- Third-party COAs with HPLC and mass spectrometry verification are non-negotiable for research-grade sourcing.
- All content and sourcing decisions should remain framed around laboratory and research use only.
Frequently Asked Questions
What is the main difference between sermorelin and CJC-1295?
Sermorelin is a short-acting GHRH(1-29) analog with a half-life of roughly 10-20 minutes and a pulsatile release pattern in research models. CJC-1295 is a modified, more stable GHRH analog available with DAC (half-life of several days, sustained signaling) or without DAC (half-life around 30 minutes, extended pulsatile signaling).
What does "CJC-1295 with DAC" mean?
DAC stands for Drug Affinity Complex — a linker that binds the peptide to serum albumin after administration in research models, extending its half-life to roughly 6-8 days and producing a sustained rather than pulsatile signaling pattern.
What does "CJC-1295 without DAC" mean?
This formulation, also called Mod GRF (1-29), omits the albumin-binding DAC linker. It retains stability-enhancing amino acid substitutions but clears faster than the DAC version, with a half-life closer to 30 minutes.
Is CJC-1295 the same as sermorelin?
No. Both are GHRH-receptor-targeting analogs, but they differ in amino acid sequence, molecular weight, and — most significantly — half-life and signaling pattern. They are not interchangeable in a research protocol.
How long does sermorelin remain active compared to CJC-1295?
Sermorelin's reported half-life is roughly 10-20 minutes. CJC-1295 without DAC runs around 30 minutes, while CJC-1295 with DAC extends to approximately 6-8 days in commonly cited research ranges.
Is CJC-1295 more stable than sermorelin?
Generally, yes — the amino acid substitutions in CJC-1295 improve resistance to enzymatic degradation relative to native-sequence sermorelin, and the DAC formulation's albumin binding further extends functional stability in research models.
Can sermorelin and CJC-1295 be studied together?
Combining two GHRH-pathway analogs with very different half-lives is less common in the literature than combining a GHRH analog with a GHRP-class compound like ipamorelin, which targets a separate receptor pathway. Any combination protocol should have a clear study rationale.
How is peptide purity measured and verified?
Legitimate suppliers use HPLC (High-Performance Liquid Chromatography) to determine purity percentage and mass spectrometry to confirm molecular identity, documented in a batch-specific certificate of analysis (COA), ideally verified by an independent third-party lab.
What does a certificate of analysis (COA) show?
A COA documents a specific batch's HPLC purity percentage, mass spectrometry-confirmed molecular identity, lot number, and — where applicable — endotoxin testing results, along with the testing lab and date.
Are sermorelin and CJC-1295 sold for human consumption?
No. Both are sold strictly for laboratory and research use. They are not intended for human consumption, and no dosing or self-administration guidance should be inferred from research literature or supplier documentation.
How should sermorelin and CJC-1295 be stored?
Lyophilized vials should be stored per supplier guidance (typically -20°C or below for long-term storage). Once reconstituted with bacteriostatic water, solutions should be refrigerated, protected from light, and used within the supplier's documented stability window.
What is bacteriostatic water and why is it used?
Bacteriostatic water is sterile water containing a small amount of benzyl alcohol to inhibit bacterial growth, commonly used to reconstitute lyophilized peptides for laboratory research applications.
Which peptide has a longer duration of action in research models, sermorelin or CJC-1295?
CJC-1295 with DAC has the longest reported duration, extending to several days versus sermorelin's 10-20 minutes, due to its albumin-binding mechanism.
How is 99 Purity Peptides' sermorelin and CJC-1295 tested for purity?
99 Purity Peptides provides third-party HPLC and mass spectrometry verification for each batch of sermorelin and CJC-1295 (both DAC and no-DAC formulations), with documentation available to researchers before purchase.
What research applications commonly study sermorelin and CJC-1295?
Both compounds appear in growth hormone axis and GHRH-receptor research literature, often in studies examining pulsatile versus sustained signaling patterns, receptor pharmacology, and peptide stability.
